173 related articles for article (PubMed ID: 23002284)
1. Immunohistochemistry in the era of personalised medicine.
McCourt CM; Boyle D; James J; Salto-Tellez M
J Clin Pathol; 2013 Jan; 66(1):58-61. PubMed ID: 23002284
[TBL] [Abstract][Full Text] [Related]
2. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
Reddy JC; Reimann JD; Anderson SM; Klein PM
Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
[TBL] [Abstract][Full Text] [Related]
3. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.
Dowsett M; Bartlett J; Ellis IO; Salter J; Hills M; Mallon E; Watters AD; Cooke T; Paish C; Wencyk PM; Pinder SE
J Pathol; 2003 Apr; 199(4):418-23. PubMed ID: 12635131
[TBL] [Abstract][Full Text] [Related]
4. [Companion diagnostics in the era of personalized medicine--chairmen's introductory remarks].
Fukutsuka K; Takubo T
Rinsho Byori; 2014 Apr; 62(4):378-80. PubMed ID: 25022067
[TBL] [Abstract][Full Text] [Related]
5. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
Stern HM; Padilla M; Wagner K; Amler L; Ashkenazi A
Clin Cancer Res; 2010 Mar; 16(5):1587-96. PubMed ID: 20179215
[TBL] [Abstract][Full Text] [Related]
6. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
Carney WP
IDrugs; 2009 Apr; 12(4):238-42. PubMed ID: 19350468
[TBL] [Abstract][Full Text] [Related]
7. The tissue is the issue: personalized medicine for non-small cell lung cancer.
Hirsch FR; Wynes MW; Gandara DR; Bunn PA
Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
[TBL] [Abstract][Full Text] [Related]
9. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J
J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
11. [Personalized, targeted treatment of non-small cell lung cancer].
Wolf J
Dtsch Med Wochenschr; 2011 Mar; 136(10):480-5. PubMed ID: 21365525
[No Abstract] [Full Text] [Related]
12. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
13. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
Heinmöller P; Gross C; Beyser K; Schmidtgen C; Maass G; Pedrocchi M; Rüschoff J
Clin Cancer Res; 2003 Nov; 9(14):5238-43. PubMed ID: 14614004
[TBL] [Abstract][Full Text] [Related]
14. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers.
Rosell R
J Clin Oncol; 2004 Apr; 22(7):1171-3. PubMed ID: 14981109
[No Abstract] [Full Text] [Related]
15. EGF receptor in lung cancer: a successful story of targeted therapy.
Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
[TBL] [Abstract][Full Text] [Related]
16. [HER-2 diagnostics].
Bánkfalvi A
Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry--a new era in diagnostic surgical pathology.
Lateef F; Kazi JI
J Pak Med Assoc; 2012 Aug; 62(8):750-1. PubMed ID: 23862241
[No Abstract] [Full Text] [Related]
18. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
[TBL] [Abstract][Full Text] [Related]
19. HER2/neu revisited: quality and interpretive issues.
Ahmed SS; Iqbal J; Thike AA; Lim AS; Lim TH; Tien SL; Tan PH
J Clin Pathol; 2011 Feb; 64(2):120-4. PubMed ID: 21131629
[TBL] [Abstract][Full Text] [Related]
20. ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry.
Tuominen VJ; Tolonen TT; Isola J
Histopathology; 2012 Apr; 60(5):758-67. PubMed ID: 22296215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
